pain control in renal impairment...care for patients with ckd and end-stage renal disease (esrd)...
TRANSCRIPT
30/10/2019
1
Pain Control in Renal Impairment
Dr Aoife Lowney Consultant in Palliative Medicine and
Renal Supportive Care October 2019
1
2
30/10/2019
2
Patients with ESRD have complex pathophysiologic mechanisms that can be
thought of as the confluence of cardiovascular disease, chronic inflammation, and bone disease that collectively drive malnutrition and medical
frailty
TIP
Care for patients with CKD and end-stage renal disease (ESRD) benefits from multidisciplinary
input from nephrology, primary care, and palliative care
TIP
3
4
30/10/2019
3
0 20 40 60 80 100
Weakness
Poor Mobility
Pain
Itch
Difficulty Sleeping
SOB
Drowsiness
Restless Legs
Appetite
Anxiety
Depression
Skin Changes
Nausea
Constipation
Vomiting
Diarrhoea
Mouth Changes
% Reporting
Symptom
Overwhelming
Severe
Moderate
Mild
Figure 1. Bar chart showing the proportion of patients reporting each symptom and the severity of the reported symptom. SOB=shortness of breath.
Lowney et al. Do patient-reported measures of symptoms and health status predict mortality in hemodialysis? An assessment of POS-S Renal and EQ-5D. 2016; 20: 618-30.
Symptom OUR STUDY
Pos-S Renal
% (mean)
COPD, CHF, cirrhosis
% (MSAS-SF) CANCER
% (MSAS-SF)
Lack energy 78% 84 73
Itching 56% 26 27
Shortness breath 55% 86 23
Pain 64% 49 63
Muscle cramps _ - -
Symptom Prevalence
Murtagh et al JPM (in press, 2007), Murtagh et al ACKD 2007 Jan 14 (1), Tranmer et al JPSM 2003 25 (5), Portenoy et al Eur J Cancer 1994 3 (3)
5
6
30/10/2019
4
Musculoskeletal pain was most common (50.5%) and equal in severity to pain associated with peripheral neuropathy and peripheral vascular disease
Pain in hemodialysis patients: prevalence, cause, severity, and management 2003
• Due to Primary Renal Disease (PKD)
• Concurrent Comorbidity (DM PN, PVD, osteoporosis, cancer, degenerative disc disease)
• Disease Consequent Upon Renal Failure (calciphylaxis, renal osteodystrophy, dialysis-related amyloid arthropathy, discitis)
Other Classification
7
8
30/10/2019
5
Multiple Causes of pain are not uncommon
“You see the empty bed” Dr K Durley 24/05/2019
Haemodialysis
• Aging population • Multiple co-morbidities
• Poor Prognosis
Figure 1.4. RRT incidence rates between 1980 and 2016
63,162 adult patients receiving renal replacement therapy in UK (2016)
9
10
30/10/2019
6
2019 Public Concern
New York Times Feb 19th 2019
11
12
30/10/2019
7
• It is reasonable to use familiar conventional opioids such as oxycodone and tramadol at low doses and at longer intervals and monitor of signs of opioid toxicity
Pain Control in Mild to Moderate CKD
13
14
30/10/2019
8
Analgesia for Patients with Severely Impaired Renal Function (CKD IV & V) and ESKD on Renal
Replacement TherapyDraft Guideline
Dr Sreenath Pillai & Dr Aoife Lowney
2. Target Audience
Clinicians managing malignant and non-malignant pain in patients with severely impaired renal function (CKD IV & V) and those on renal replacement therapy
Not intended as a guide to post-operative pain management
Pharmacologic focus
15
16
30/10/2019
9
3. Stakeholder Involvement
• Renal MDT including renal pharmacist
• Palliative Medicine Medicines Management Group including pharmacy and CCG representation
• Pain Team
4. Methods
• A Medline search (using the search words – Chronic renal failure / ESRF / advanced chronic kidney disease / dialysis/haemodialysis / haemodiafiltration / haemofiltration / peritoneal dialysis /analgesia/consensus/consensus development / guideline / policy statement)
• As there are no large RCTs or Systematic reviews, available guidelines were also used to make recommendations
• Renal drug Database and palliative care formulary were also referred for guidance
17
18
30/10/2019
10
5. ASSESSMENT OF PAIN & ASSESSMENT OF RENAL FUNCTION
Assessment
• Chronicity of pain and reversible Factors
• Type of pain and aetiology of pain
• Treatment goals
19
20
30/10/2019
11
Patient Reported Outcome Measures
• POS-S (renal)
• Brief pain inventory
• Short-Form McGill Pain Questionnaire (SF-MPQ)
• Modified Edmonton Symptom Assessment System (mESAS
• Dialysis symptom index (DSI)
Creatinine Clearance v eGFR
• OUH reports renal function in adults based on estimated glomerular filtration rate (eGFR) normalised to a body surface area of 1.73 m2—(MDRD) formula
• The information on dosage adjustment in the BNF is usually expressed in terms of eGFR
• In product literature, the effects of renal impairment on drug elimination is usually stated in terms of creatinine clearance as a surrogate for GFR
21
22
30/10/2019
12
Basic principles of pain management
• ‘By mouth’ (when feasible - Transdermal route/subcutaneous if oral route difficult).
• ‘By the clock’ (at regular intervals & additional breakthrough should be available as PRN)
• ‘For the individual’ (against Individual needs)’
• ‘Attention to detail’ (watch for toxicity and laxatives when using regular opioids).
Basic principles of pain management
• ‘By mouth’ (when feasible - Transdermal route/subcutaneous if oral route difficult).
• ‘By the clock’ (at regular intervals & additional breakthrough should be available as PRN)
• ‘For the individual’ (against Individual needs)’
• ‘Attention to detail’ (watch for toxicity and laxatives when using regular opioids).
23
24
30/10/2019
13
Basic principles of pain management
• ‘By mouth’ (when feasible - Transdermal route/subcutaneous if oral route difficult).
• ‘By the clock’ (at regular intervals & additional breakthrough should be available as PRN)
• ‘For the individual’ (against Individual needs)’
• ‘Attention to detail’ (watch for toxicity and laxatives when using regular opioids).
Basic principles of pain management
• ‘By mouth’ (when feasible - Transdermal route/subcutaneous if oral route difficult)
• ‘By the clock’ (at regular intervals & additional breakthrough should be available as PRN)
• ‘For the individual’ (against Individual needs)’
• ‘Attention to detail’ (watch for toxicity and laxatives when using regular opioids)
25
26
30/10/2019
14
WHO
Step 3
Step 1
Step 2
Paracetamol
NSAIDs with nephrologist agreement
Opioids to Avoid
• Codeine (metabolised to morphine)
• Tramadol (synthetic related to codeine)
• Morphine
• (Oxycodone)
27
28
30/10/2019
15
WHO
Step 3
Step 1
Step 2
Paracetamol
NSAIDs with nephrologist agreement
WHO
Step 3
Step 1
Step 2
(Hydromorphone)
Fentanyl
Alfentanil
Methadone
Bupenorphine
Paracetamol
NSAIDs with nephrologist agreement
29
30
30/10/2019
16
Opioids to Avoid
• Codeine
• Tramadol
• Morphine
• (Oxycodone)
Oxycodone
• Semisynthetic opioid CYP3A4 noroxycodone (active) & CYP2D6 oxymorphone (active)
• Parent drug and active metabolites appear to accumulate in CKD• Recent systematic review -2 studies : adverse events 50% those with
severe CKD v 14% normal renal function (20mg) • Similar analgesic and side effect profile as morphine• HD- study of 20 patients no loss of analgesia
• In the absence of availabilty of hydromorphone: • Recommendations: 1-2mg IR twice a day to start with and titrate up to
maximum of 10mg in 24hrs using short-acting formulation only. • Once pain is controlled consider switching to Transdermal fentanyl or
Buprenorphine. Consult pain/pall med services if encountering difficulties.
31
32
30/10/2019
17
Opioids that are recommended
• (Hydromorphone)
• Buprenorphine
• Fentanyl
• Alfentanil
• Methadone (specialist use)
(Hydromorphone)USA/Canada/Aus/Ire
• Potent μ receptor agonist • Extensive 1st pass to H3G- no analgesic activity
but OIN• H3G removed by HD without a change in pain
scores • Pharmacokinetics parent compound not
substantially altered by CKD ?due to rapid conversion to H3G (trace amounts)
• 0.5mg every 4-6 hrs PO
33
34
30/10/2019
18
Buprenorphine (transdermal)
• Potent semi synthetic opioid & partial μ receptor agonist • Metabolised in liver, eliminated mainly in faeces• Two metabolites: B3G(inactive) and norbuprenorphine (less active)-
excreted through urine• Onset of action: 18-24hrs • Time to peak plasma concentrations: 3 days • Plasma half-life unchanged in CKD (BuTrans): 13-35hrs (after a patch has
been removed & not replaced)• Dialysis- no changes in buprenorphine levels pre & post haemodialysis,
giving stable pain relief • Difficult to reverse with Naloxone due to high mu affinity• Recommendations: Start with 5mcg/hr Patch or Use opioid converting
table to find an equivalent dose –
Fentanyl • Synthetic μ agonist• Compared to Morphine, Fentanyl is 50-100 times potent and 1000
times lipophilic – ideal for transdermal delivery. • Onset of action: 3-23 hrs & steady state plasma concentrations are
achieved in 36-48 hrs • Patients continue to receive the drug up to 24 hours after removal
of patch due to subcutaneous depot • Less histamine release, low incidence of constipation and more
cardiovascular stability than morphine• Poor oral bioavailability. Metabolised in liver (inactive metabolites)
with 5-10% excreted in urine unchanged• No clinically significant accumulation in renal impairment.• Not dialysed (PD/HD)
35
36
30/10/2019
19
Transdermal Opioids• In Opioid Naive patients, please consider
Buprenorphine patches. Because,
• 5mcg/hr Buprenorphine = 10mg Morphine/24 hrs (oral)
• 12mcg/hr Fentanyl = 45mg Morphine/24hrs (oral)
• Usually used when pain is stable.
• DO NOT ADJUST PATCH STRENGTH DAILY.
Alfentanil - Specialist (Palliative
medicine/Pain Team) use only
• Not dialysed
• Recommendations: Opioid of choice for syringe driver use in patients with eGFR<30ml/min/1.73m2. Please consult Palliative Medicine team as per OUH Trust guidelines
37
38
30/10/2019
20
Methadone
• Palliative medicine/Pain/Hospice Use only• Potent synthetic opioid mainly acting at the μ receptor• NMDA antagonist • Hepatic metabolism to inactive metabolites with 20%
excreted unchanged in urine (in anuria excreted in faeces – no accumulation)
• No T1/2 change in CKD but slower release from tissue reservoirs
• Not removed by HD• 1-2mg very 12-24 hours
Adjuvants
• Gabapentin√ (100mg alt days or 100mg after each HD)
• Pregabalin√ (25mg alt days or 25mg after each HD)
• Carbamazepine√
• Amitriptyline (no dose reduction required but 10mg nocte recommended)
• Ketamine (no dose reduction- not studied in HD)
39
40
30/10/2019
21
BREAKTHROUGH PAIN
“A transient exacerbation of pain that occurs eitherspontaneously, or in relation to a specific predictable orunpredictable trigger, despite relatively stable andadequately controlled background pain”
Davies AN (2009). The management of cancer-related breakthrough pain:
European Journal of Pain, 13, 331-8.
Definition
41
42
30/10/2019
22
Breakthrough Cancer Pain
Spontaneous Pain
Incident PainVolitional ( eg Walking)
Non-
volitional
Procedural
Oral Morphine Profile
BTP Profile Overmedication
Pain relief gap
Time (minutes)5 30 60
Pain
In
ten
sity
BTP Profile
43
44
30/10/2019
23
BTcP Therapies: Target Product Profile
• Concentration–time profile that closely mirror the
pain intensity–time profile of the BTcP episode
• Delivery systems with potential to:
– Enhance dissolution
– Enhance absorption
– Minimize the first-pass effect
Fentanyl
Estimated potency of 80 to 100 times that of morphine
1. Anderson R et al. J Pain Symptom Manage. 2001;21:397-400.
2. Pereira J et al. J Pain Symptom Manage. 2001;22:672-687.
BTcP Therapies: Delivery Systems
1998 2006/2008 2009 2008
Oral trans
-mucosal
fentanyl
citrate
OTFC
FENTORA®(US)/
EFFENTORA™(EU)ONSOLIS™
(US) FBSF
Rapinyl™/
Abstral
(EU) SLF
2009
Instanyl™(EU) INFS
2009
Nasalfent ®
(EU) FPNS
Effervescent Buccal
TabletFentanyl Buccal
Soluble Film
Oral
Transmucosal
Lozenge
Intranasal
Fentanyl Spray
Sublingual
FentanylF Pectin
Nasal Spray
45
46
30/10/2019
24
Special Circumstances
Gout:
• Observational studies demonstrate that CKD is the third most common independent risk factor for gout after obesity and hypertension
• Colchicine: Reduce dose by 50% in patients with GFR 10-50ml/min. • GFR <10 : 500mcg, 3-4 times/day (max of 3mg) (7)
HD/PD - Dose as in GFR <10.
• NSAIDs: See earlier discussions.•
• Glucocorticoids: Short course 0.5mg/kg/day.
47
48
30/10/2019
25
• Muscle cramps: – Despite lack of large studies, Quinine remains the
main stay of treatment for dialysis associated muscle cramps. Attention must be given to optimising other factors such as fluid shift and dry weight adjustments. • Quinine sulphate 300mg prior to HD session• Magnesium supplementation
• Restless legs/Itch :– Gabapentin has been found to be useful in restless
legs and also useful in treating itch
Calciphylaxis:
• Mixed nociceptive and neuropathic pain
• Difficult to manage
• Specialist palliative medicine support should be sought early
• For those who don’t respond, consider NMDA receptor antagonists (methadone or Ketamine)
49
50
30/10/2019
26
Quick ReferenceStep 1.
Paracetamol (1g four times daily per orally)
NSAIDs – Usage restricted in anuric dialysis patient, only after discussion with renal team
Topical NSAIDs
Step 2.
Oxycodone (1-2mg twice a day to start with and titrate up to maximum of 10mg in 24hrs. Once pain stabilised, consider switching to buprenorphine/fentanyl patch)
Step 3
Buprenorphine Patch: dose equivalent to previous opioid or start with 5 mcg/hr and change every 7 days
OR
Fentanyl Patch: only when pain is stable ( for dose equivalence use the description/opioid conversion table above )
Step 4. Difficult to control pain or Patient may need Alfentanil or Methadone or Ketamine - Please Contact Pain team Or Palliative Medicine for review
Neuropathic Pain – Consider Adjuvants: Eg.,Gabapentin (see Detailed guidelines)
51
52
30/10/2019
27
53
54